이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Amgen 관리
관리 기준 확인 3/4
Amgen's CEO는 Bob Bradway, May2010 에 임명되었습니다 의 임기는 14.08 년입니다. 총 연간 보상은 $ 22.64M, 7.9% 로 구성됩니다. 7.9% 급여 및 92.1% 보너스(회사 주식 및 옵션 포함). 는 $ 190.61M 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 190.61M. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 7.5 년입니다.
주요 정보
Bob Bradway
최고 경영자
US$22.6m
총 보상
| CEO 급여 비율 | 7.9% |
| CEO 임기 | 14.1yrs |
| CEO 소유권 | 0.1% |
| 경영진 평균 재임 기간 | 4.8yrs |
| 이사회 평균 재임 기간 | 7.5yrs |
최근 관리 업데이트
Recent updates
Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04
Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?
Oct 23Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Sep 22Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?
Sep 04Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13
Aug 05Amgen Inc. (NASDAQ:AMGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 30Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year
May 09These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Reasonably Well
Apr 29CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$23m | US$2m | US$7b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$7b |
| Dec 31 2020 | US$20m | US$2m | US$7b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$20m | US$2m | US$8b |
| Sep 30 2019 | n/a | n/a | US$8b |
| Jun 30 2019 | n/a | n/a | US$8b |
| Mar 31 2019 | n/a | n/a | US$8b |
| Dec 31 2018 | US$19m | US$2m | US$8b |
| Sep 30 2018 | n/a | n/a | US$2b |
| Jun 30 2018 | n/a | n/a | US$2b |
| Mar 31 2018 | n/a | n/a | US$2b |
| Dec 31 2017 | US$17m | US$2m | US$2b |
보상 대 시장: Bob 의 총 보상 ($USD 22.64M )은 US 시장( $USD 13.52M ).
보상과 수익: Bob 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Bob Bradway (61 yo)
14.1yrs
테뉴어
US$22,643,650
보상
Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 14.1yrs | US$22.64m | 0.12% $ 192.3m | |
| Executive VP & CFO | 4.4yrs | US$7.57m | 0.0046% $ 7.6m | |
| Executive Vice President of Operations | 7.9yrs | US$7.21m | 0.011% $ 18.8m | |
| Executive VP & Chief Technology Officer | less than a year | US$7.90m | 0.0094% $ 15.4m | |
| Executive Vice President of Global Commercial Operations | 5.8yrs | US$8.24m | 0.0075% $ 12.3m | |
| Chief Accounting Officer & VP of Finance | less than a year | 데이터 없음 | 0.00056% $ 919.2k | |
| Senior VP & Chief Information Officer | 5.4yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP of Research and Development & Chief Scientific Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP | 8.9yrs | US$7.24m | 0.0047% $ 7.6m | |
| Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | 4.4yrs | 데이터 없음 | 0.0010% $ 1.7m | |
| Senior Vice President of Global Marketing | 4.8yrs | 데이터 없음 | 데이터 없음 |
4.8yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 관리: AMGN 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 12.7yrs | US$22.64m | 0.12% $ 192.3m | |
| Lead Independent Director | 11.5yrs | US$419.92k | 0.0013% $ 2.2m | |
| Co-Chair of Scientific Advisory Board | no data | US$292.01k | 데이터 없음 | |
| Co-Chair of the Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.9yrs | US$359.92k | 0.000080% $ 131.3k | |
| Independent Director | 7.3yrs | US$369.92k | 0.00023% $ 377.5k | |
| Independent Director | 10.7yrs | US$379.92k | 0.0023% $ 3.8m | |
| Independent Director | 7.7yrs | US$360.29k | 0.000080% $ 131.3k | |
| Independent Director | 6.1yrs | US$359.92k | 0.00015% $ 246.2k | |
| Independent Director | 12.1yrs | US$339.92k | 0.00051% $ 837.1k | |
| Independent Director | 6.5yrs | US$359.92k | 0.0012% $ 2.0m | |
| Independent Director | 2.9yrs | US$366.47k | 0.00017% $ 279.0k |
7.5yrs
평균 재임 기간
68yo
평균 연령
경험이 풍부한 이사회: AMGN 의 이사회는 경험(평균 재직 기간 7.5 년)으로 간주됩니다.